• Vaccine Name: ADS-MVA vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: S protein(Chen et al., 2005)
• S protein gene of SARS-CoV gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: Recombinant live-attenuated modified vaccinia virus Ankara (MVA) had full-length SARS-CoV envelope Spike (S) glycoprotein gene was introduced into the deletion III region of the MVA genome.
  (Chen et al., 2005)

Macaque Response

• Vaccination Protocol: immunized intramuscular injection twice with a 4-week interval. 1 × 10^8 TCID50 for the first immunization and a dose of 3 × 10^8 TCID50 for the second injection. (Chen et al., 2005)
• Immune Response: testing hosts generated high levels of neutralizing antibodies after 2 vaccinations
  (Chen et al., 2005)
• Challenge Protocol: immunized on days 0 and 28 via intranasal injection before challenged after second immunization on day 28 with 10^5 TCID50 of pathogenic SATS-CoVPUMC01.
  (Chen et al., 2005)
• Efficacy: likely protected (Chen et al., 2005)
• Description: After virus challenge, SARS-CoV shedding detected by RT-PCR was only detected in the nasopharyngeal specimens of one of the four ADS-MVA immunized animals (Rh0413) on day 2 after virus challenge. No virus shedding was detectable on days 4 and 6 postchallenge in these four macaques. SARS-CoV could not be isolated from the lung specimens of ADS-MVA-immunized macaques on day 7 postchallenge. (Chen et al., 2005)

Mouse Response

• Host Strain: Balb/c (Chen et al., 2005)
• Host age: 6-8 weeks (Chen et al., 2005)
• Host gender: Female (Chen et al., 2005)
• Vaccination Protocol: immunized intramuscular injection twice with a 3-week interval. Two mice were given 2 × 106 TCID50 of the vaccine, and six mice received 2 × 10^7 TCID50.(Chen et al., 2005)
• Immune Response: testing hosts generated high levels of neutralizing antibodies (Chen et al., 2005)

Rabbit Response

• Vaccination Protocol: immunized intramuscular injection twice with a 3-week interval (Chen et al., 2005)
• Immune Response: testing hosts generated high levels of neutralizing antibodies (Chen et al., 2005)

Ferret Response

• Host age: 6-10 weeks (Weingartl et al., 2004)
• Host gender: Male (Weingartl et al., 2004)
• Vaccination Protocol: Each ferret was immunized with rMVA-S (ferrets 7 to 9), n day 0 with a dose of 1e8 PFU of the corresponding virus per ferret by intraperitoneal and subcutaneous routes, and a booster immunization was given on day 14 with the same regimen.(Weingartl et al., 2004)
• Immune Response: Neutralizing activity was detected in sera along with a corresponding immunoglobin G titer collected from all three ferrets 7 days after booster immunization with rMVA-S virus, while the titer declined to undetectable level 14 days after the booster (Weingartl et al., 2004).
• Side Effects: Ferrets immunized with rMVA-S (particularly ferret 9) developed severe periportal and panlobular mononuclear hepatitis in contrast to only mild periportal mononuclear hepatitis was observed in control ferrets (Weingartl et al., 2004) .
• Challenge Protocol: Ferrets were challenged with 1e6 PFU of the SARS-CoV Tor2 isolate by the intranasal route(Weingartl et al., 2004).
• Description: Study shows correlation with liver damage but does not definitely proof it is caused as SARS-CoV in ferrets also damage liver.(Weingartl et al., 2004)